Explore › Finding
Finding null
Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining within normal limits throughout the study.
Effect sizeall parameters within normal limits throughout the study
Follow-up12 weeks
ComparatorMismatch control antisense oligonucleotide (same dose, same schedule)
Effect summarynull; all parameters within normal limits throughout the study

Connected entities

Interventions
Anti-miR-33 antisense oligonucleotide
Conditions
Dyslipidemia
Outcomes
Clinical chemistries

Source

PMC3235584
Inhibition of miR-33a/b in non-human primates raises plasma HDL and reduces VLDL triglycerides
Read on PMC → · View in graph →